Strategic funding Nammi Therapeutics has recently secured a Series B financing with a $1M commitment from the Myeloma Investment Fund as part of a $30M round, signaling investor confidence and potential for accelerated clinical development and partnering discussions with biopharma due to upcoming first-in-human trials.

Clinical momentum With plans to start a first-in-human Phase 1 study for lead candidate QXL138AM and multiple Nammisome clinical candidates in development, there are compelling conversations to initiate collaborations on translational research, biomarker strategies, and potential co-development opportunities.

Targeted delivery advantage Nammi’s focus on tumor microenvironment specific activation and reduced systemic immunity presents a value proposition for sponsors seeking safer combination regimens, enabling partner-led trials that explore synergy with existing IO modulators and monoclonal antibodies.

Platform breadth Beyond the MIC platform, Nammi has a nanoparticle based Nammisome technology for Immune Modulating Prodrugs, implying multiple collaboration avenues in nanomedicine, targeted delivery, and controlled release strategies potentially attractive to research or venture partners.

Strategic partnerships Recent investment from the Myeloma Investment Fund and the company’s focused oncology positioning in multiple myeloma create openings for business development conversations around strategic alliances, licensing, or co-development deals with larger biotech majors pursuing immuno-oncology portfolios.